Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma

Human Pathology

Volumn 40, Issue 10, 2009, Pages 1441-1447

  Li, Yi ^a   Meng, Gang ^a   Huang, Lei ^a   Guo, Qiao Nan ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Differentially methylated region (DMR); IGF2, P3 promoter; Methylation; Osteosarcoma

Indexed keywords

CYTOSINE; SOMATOMEDIN B;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENOME IMPRINTING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PROMOTER REGION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; UPREGULATION;

ADOLESCENT; ADULT; BASE SEQUENCE; BONE NEOPLASMS; CHILD; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC IMPRINTING; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR II; MALE; MOLECULAR SEQUENCE DATA; OSTEOSARCOMA; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 69949174705     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.03.003     Document Type: Article

References (34)

1. Jones P.A. Epigenetics in carcinogenesis and cancer prevention. Ann N Y Acad Sci 983 (2003) 213-219
2. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 329 (2003) 2042-2054
3. Sadikovic B., Al-Romaih K., Squire J.A., et al. Cause and consequences of genetic and epigenetic alterations in human cancer. Current Genomics 9 (2008) 394-408
4. Goldstein M., Meller I., and Orr-Urtreger A. FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5′ CpG Island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chromosomes Cancer 46 (2007) 1028-1038
5. Furstenberger G., and Senn H.J. Insulin-like growth factors and cancer. Lencet Oncol 3 (2002) 298-302
6. Li X., Cui H., Sandstedt B., et al. Expression levels of the insulin-like growth factor-II gene (IGF2) in the human liver: developmental relationships of the four promoters. J Endocrinol 149 (1996) 117-124
7. Eriksson T., Frisk T., Gray S.G., et al. Methylation changes in the human IGF2 p3 promoter parallel IGF2 expression in the primary tumor, established cell line, and xenograft of a human hepatoblastoma. Exp cell Res 270 (2001) 88-95
8. Ohlsson R. Loss of IGF2 imprinting: mechanisms and consequences. Novartis Found Symp 262 (2004) 108-121
9. Kaneda A., and Feinberg A.P. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 65 (2005) 11236-11240
10. Cui H., Onyango P., Brandenburg S., et al. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 62 (2002) 6442-6446
11. Cui H., Cruz-Correa M., Giardiello F.M., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299 (2003) 1753-1755
12. Sayer R.A., Lancaster J.M., Pittman J., et al. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol Oncol 96 (2005) 355-361
13. Breuhahn K., Vreden S., Haddad R., et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 64 (2004) 6058-6064
14. Zumkeller W. The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches. Sarcoma 2 (1998) 69-76
15. Sun Y., Gao D., Liu Y., et al. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 25 (2006) 1042-1052
16. Tsuchiya T., Sekine K., Hinohara S., et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet 120 (2000) 91-98
17. Kawaguchi K., Oda Y., Sakamoto A., et al. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol 15 (2002) 878-888
18. Benassi M.S., Molendini L., Gamberi G., et al. Involvement of INK4A gene products in the pathogenesis and development of human osteosarcoma. Cancer 92 (2001) 3062-3067
19. De Pagter-Holtuizen P., Jansen M., Van der Kammen R.A., et al. Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II-associated protein. Biochim Biophys Acta 950 (1988) 282-295
20. Uchida K., Kondo M., Takeda S., et al. Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma. Mol Carcinog 18 (1997) 193-198
21. Li Y., Meng G., and Guo Q.N. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol 84 (2008) 234-239
22. Tadokoro K., Fujii H., Inoue T., et al. Polymerase chain reaction (PCR) for detection of ApaI polymorphism at the insulin like growth factor II gene (IGF2). Nucleic Acids Res 19 (1991) 6967
23. Ulaner G.A., Vu T.H., Li T., et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 12 (2003) 535-549
24. Bohula E.A., Playford M.P., Macaulay V.M., et al. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. Anticancer Drugs 14 (2003) 669-682
25. Tang S.H., Yang D.H., Huang W., et al. Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population. Clin Cancer Res 12 (2006) 4171-4177
26. Kim S.J., Park S.E., Lee C., et al. Alterations in promoter usage and expression levels of insulin-like growth factor-II and H19 genes in cervical carcinoma exhibiting biallelic expression of IGF-II. Biochim Biophys Acta 1586 (2002) 307-315
27. Bell A.C., and Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405 (2000) 482-485
28. Ulaner G.A., Yang Y.W., Hu J.F., et al. CTCF binding at the insulin-like growth factor-II (IGF2)/H19 imprinting control region is insufficient to regulate IGF2/H19 expression in human tissues. Endocrinology 144 (2003) 4420-4426
29. Feniberg A.P. Cancer epigenetics takes center stage. Proc Natl Acad Sci 98 (2001) 392-394
30. Jang S.J., Soria J., Wang L., et al. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res 61 (2001) 7959-7963
31. Ogishima T., Shiina H., Breault J.E., et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 11 (2005) 1028-1036
32. Feinberg A.P. A genetic approach to cancer epigenetics. Cold Spring Harb Symp Quant Biol 70 (2005) 335-341
33. Hauben E.I., Bielack S., Grimer R., et al. Clinico-histologic parameters of osteosarcoma patients with late relapse. Eur J Cancer 42 (2006) 460-466
34. Hauben E.I., Weeden S., Pringle J., et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38 (2002) 1218-1225